NEW YORK (GenomeWeb News) – Epigenomics this week said that has launched a study of its Epi proColon test to examine adoption patterns in the market.
The German molecular diagnostics firm launched the colorectal cancer test in Europe in 2009. It is currently being marketed by Epigenomics to privately insured individuals and self-payors in Germany, Austria, and Switzerland and through distributors in other markets, the firm said.
Epigenomics said that it expects the study to include around 300 primary care physicians and up to 3,000 patients getting the Epi proColon test in Germany and Switzerland.
"We expect the results of this study to help with both fine-tuning the positioning of the test in the self-payor market segment and in seeking general reimbursement under the public health care scheme," Juergen Beck, SVP of medical affairs for Epigenomics, said in a statement.